Belgium Neurology Clinical Trials Market Report 2022 to 2030

Belgium Neurology Clinical Trials Market Analysis

$ 3999

The Belgium Neurology Clinical Trials market is projected to grow from $11.5 Mn in 2022 to $17.7 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022 - 2030. The market will be driven by the rising prevalence of neurological disorders and a favourable regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include UCB, Biogen Inc & Icometrix.

ID: IN10BECT005 CATEGORY: Clinical Trials GEOGRAPHY: Belgium AUTHOR: Vidhi Upadhyay

Buy Now

Belgium Neurology Clinical Trials Market Executive Summary

The Belgium Neurology Clinical Trials market is projected to grow from $11.5 Mn in 2022 to $17.7 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022 - 2030. Belgium is a significant pharmaceutical export centre and one of Europe's leading manufacturers. Prior to the outbreak of the Covid-19 epidemic, the small nation contributed 13% of the EU's pharmaceutical exports and 10% of pharmaceutical R&D investment in 2019. Alzheimer's and dementia fatalities in Belgium reached 9,416 in 2020, accounting for 10.17% of total deaths, according to the most recent WHO statistics. Belgium ranks 27 worldwide with an age-adjusted death rate of 22.30 per 100,000 inhabitants. An estimated 100,000 persons in Belgium suffer from epilepsy.

In Belgium, clinical trials for different neurological conditions, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy, are now underway. Some of these studies are sponsored by pharmaceutical firms, while others are supported by academic institutions or the government. Belgium has a distinct environment that allows it to position itself as a clinical trials centre. With over 70 hospitals, including 7 academic hospitals, 12 universities with globally known life sciences departments and research teams, and over 50 pharmaceutical businesses participate in clinical research and development. The Belgian government has created a favourable regulatory framework for clinical trials, with legislation aimed at encouraging research while preserving participant safety and ethical concerns. The Federal Agency for Medicines and Health Products (FAMHP) is in charge of supervising clinical trial legislation in Belgium and guaranteeing conformity with international criteria. Moreover, Belgium is a member of the European Union (EU), and as such, it adheres to the EU's clinical trial laws. This enables simple access to a vast and diversified patient population across various nations, enhancing clinical trial efficiency and cost-effectiveness.

Belgium Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

Many reasons, including the country's well-developed healthcare system, robust clinical research infrastructure, and favourable regulatory environment, are driving the rise of neurology clinical trials in Belgium. Moreover, Belgium's participation in the European Union offers easy access to a diversified patient population across various nations, enhancing clinical trial efficiency and cost-effectiveness. Belgium's renowned research institutes and hospitals such as University Hospitals Leuven, Cliniques Universitaires Saint, Universitair Ziekenhuis Antwerpen (UZA), Ghent University Hospital, CHU de Liège and many more make it an appealing destination for clinical trials. The nation offers a big pool of possible trial participants, and the availability of skilled healthcare experts and research workers helps to ensure that high-quality studies are conducted.

Market Restraints

There are other constraints to performing clinical trials in Belgium, such as the high cost of studies, which may discourage certain corporations from engaging in research in the nation. Moreover, since Belgium is a popular destination for clinical trials in a variety of therapeutic areas, recruiting and retention of trial participants may be difficult. Another possible impediment is Belgium's complicated regulatory framework for clinical studies. Although the regulatory climate is generally supportive, compliance with rules may be difficult and time-consuming, particularly for small and medium-sized businesses with limited resources.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis AG
Janssen Pharmaceutical (Johnson & Johnson)
UCB (BEL)
Biogen Inc.
Sanofi S.A.
Icometrix (BEL)

Notable Deals

January 2023, The FDA approved Eisai, a Biogen Alzheimer's drug.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.